Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Area of interest

Area of interest

Type

Type

Guidance programme

Showing 1 to 22 of 22

TitleReference numberPublishedLast updated
Trastuzumab deruxtecan for treating HER2-mutated advanced non-small-cell lung cancer after platinum-based chemotherapy (terminated appraisal)TA976
Dabrafenib with trametinib for treating BRAF V600E mutation-positive glioma in children and young people aged 1 year and overTA977
Zanubrutinib with obinutuzumab for treating relapsed or refractory B-cell follicular lymphoma after 2 or more treatments (terminated appraisal)TA978
Setmelanotide for treating obesity and hyperphagia in Bardet-Biedl syndromeHST31
Alemtuzumab for treating highly active relapsing–remitting multiple sclerosisTA312
Natalizumab for the treatment of adults with highly active relapsing–remitting multiple sclerosisTA127
Cladribine for treating relapsing–remitting multiple sclerosisTA616
Ranibizumab for treating choroidal neovascularisation associated with pathological myopiaTA298
Ranibizumab and pegaptanib for the treatment of age-related macular degenerationTA155
Ranibizumab for treating visual impairment caused by macular oedema secondary to retinal vein occlusionTA283
Selective internal radiation therapy for neuroendocrine tumours that have metastasised to the liverHTG720
Endoscopic duodenal mucosal resurfacing for insulin resistance in type 2 diabetesHTG721
Image-guided percutaneous laser ablation for primary and secondary liver tumoursHTG722
Atogepant for preventing migraineTA973
Selinexor with bortezomib and dexamethasone for previously treated multiple myelomaTA974
Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 25 years and underTA975
Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancerHTG719
Selinexor with dexamethasone for treating relapsed and refractory multiple myeloma after 4 or more treatmentsTA970
Remdesivir and tixagevimab plus cilgavimab for treating COVID-19TA971
Artificial intelligence (AI)-derived software to help clinical decision making in strokeHTG708
Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphomaTA540
Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma in people 3 years and overTA967

Results per page

  1. 10
  2. 25
  3. 50
  4. All